Amgen Inc. (NASDAQ:AMGN) Position Decreased by Oakbrook Investments LLC
Oakbrook Investments LLC lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 1.3% during the second quarter, Holdings Channel reports. The firm owned 216,314 shares of the medical research company’s stock after selling 2,845 shares during the period. Amgen makes up approximately 2.5% of Oakbrook Investments LLC’s portfolio, making the stock its 3rd largest position. Oakbrook Investments LLC’s holdings in Amgen were worth $37,256,000 at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in the stock. TrimTabs Asset Management LLC raised its position in shares of Amgen by 88.9% in the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock valued at $100,000 after buying an additional 288 shares during the period. Alpha Omega Wealth Management LLC raised its position in shares of Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock valued at $103,000 after buying an additional 100 shares during the period. Jackson Grant Investment Advisers Inc. raised its position in shares of Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares during the period. American Beacon Advisors Inc. purchased a new position in shares of Amgen during the first quarter valued at approximately $106,000. Finally, Nelson Roberts Investment Advisors LLC purchased a new position in shares of Amgen during the first quarter valued at approximately $121,000. Hedge funds and other institutional investors own 79.53% of the company’s stock.
Amgen Inc. (NASDAQ:AMGN) traded down 1.94% on Thursday, reaching $170.19. The company had a trading volume of 951,359 shares. The company has a market capitalization of $124.18 billion, a P/E ratio of 15.50 and a beta of 1.35. The stock’s 50-day moving average is $174.67 and its 200-day moving average is $167.36. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $184.21.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. The business had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The business’s revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the firm earned $2.84 EPS. Equities research analysts forecast that Amgen Inc. will post $12.57 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Thursday, August 17th will be issued a dividend of $1.15 per share. The ex-dividend date of this dividend is Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.65%. Amgen’s dividend payout ratio is currently 41.93%.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/10/amgen-inc-nasdaqamgn-position-decreased-by-oakbrook-investments-llc.html.
Several brokerages have recently commented on AMGN. BMO Capital Markets lowered Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 price objective on the stock. in a research report on Friday, July 21st. They noted that the move was a valuation call. Jefferies Group LLC restated a “hold” rating and set a $180.00 target price on shares of Amgen in a report on Monday, May 22nd. Leerink Swann restated a “market perform” rating and set a $161.00 target price on shares of Amgen in a report on Thursday, June 22nd. Credit Suisse Group set a $177.00 target price on Amgen and gave the company a “hold” rating in a report on Friday, July 14th. Finally, Cowen and Company restated an “outperform” rating and set a $209.00 target price on shares of Amgen in a report on Wednesday, April 19th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company’s stock. Amgen presently has an average rating of “Buy” and a consensus price target of $186.64.
In other news, SVP Cynthia M. Patton sold 2,922 shares of the firm’s stock in a transaction that occurred on Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the sale, the senior vice president now owns 24,214 shares in the company, valued at approximately $3,738,641.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.20% of the stock is owned by company insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.